Business Wire

JDI

23.8.2024 09:01:29 CEST | Business Wire | Press release

Share
JDI Develops World's First Automotive Grade Dual Touch 2 Vision Display (2VD)

This press release is intended to redistribute the content that was already disclosed on August 2, 2024, for an international audience.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240823676155/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

2 Vision Display (Graphic: Business Wire)

JDI has developed the world's first 2 Vision Display (2VD) technology that meets automotive grade image quality requirements while simultaneously displaying different image content based on viewing direction. As another world's first, JDI has incorporated Dual Touch into its new 2VD technology that identifies discrete touch operations from different users. JDI Dual Touch 2VD thus enables a single display to function as two separate touch-enabled displays.

2VD has existed as a concept for many years. Unfortunately, it has historically been unable to overcome image quality issues to achieve commercialization and product use.

With its new Dual Touch 2VD technology, JDI has deployed its world-leading LTPS and optics capabilities to generate the necessary breakthrough in image quality to allow for widespread use. As an automotive use case, JDI Dual Touch 2VD simultaneously provides a large-screen, rich-content information display to the driver to support safe driving and a large-screen, high-quality passenger display on a single display. Dual Touch 2VD also resolves interior design constraints caused by the increase in displays, while allowing the reduction of in-car display usage to support streamlined and sophisticated interior designs.

2VD has also historically lacked touch functionality, an important capability for many use cases. JDI Dual Touch 2VD uses JDI-developed custom ICs to identify whether touch operations originate from the driver or passenger (again, using an automotive use case example), allowing a single display to function as two separate touch-enabled displays.

JDI is currently in discussions with multiple global automobile OEMs to incorporate JDI Dual Touch 2VD into their next-generation vehicle interiors, with first shipment possible as early as 2025. In collaboration with these OEMs, JDI is working to create unprecedented levels of automobile safety and comfort.

Existing 2VD vs. New JDI Dual Touch 2VD

 

 Existing 2VD

New JDI

Dual Touch 2VD

Resolution

88 ppi

171 ppi

Brightness

350 nits

700 nits

Contrast

350 : 1

1000 : 1

NTSC Ratio

70%

85%

Touch Functionality

None

Dual Touch

Furthermore, JDI Dual Touch 2VD’s rich functionality goes beyond the automotive industry. It has a broad set of use cases in an extraordinarily rich variety of contexts, locations, and industries and in both horizontal and vertical 2VD modes. As examples, JDI Dual Touch 2VD can be deployed in large signage applications or to create display security and privacy enhancements through viewing angle control, or to support innovative gaming applications.

A sample vertical use case of JDI Dual Touch 2VD would be a large display at a transportation hub such as an airport or train station, in which the changing user viewing angle, depending on the distance between the display and the user, allows for the simultaneous provision of rich visuals, art or other creative content, general information, or advertising (at a distance) and departure/arrival information (up close).

JDI Dual Touch 2VD is a breakthrough display technology that has the potential to change the way displays are used – and shared – all over the world in fundamentally new ways. JDI looks forward to open innovation and collaboration with individuals, organizations, and creative communities globally to explore new use cases for JDI Dual Touch 2VD that enrich people’s daily lives. Please feel free to contact us at:
https://www.webcoms.jp/jdi/eng/form.php?pid=524

2 Vision Display presentation video
https://youtu.be/zBnz1GirUYE

[Provisional Translation Only]
This translation is provided solely for information purposes.
Should there be any discrepancies between this translation and the Japanese original, the latter shall prevail.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240823676155/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

DCX builds coolant chemistry control into its 8 MW Facility Distribution Unit19.10.2026 14:01:00 CEST | Press release

DCX introduces groundbreaking new safety standard protecting critical AI infrastructure by monitoring and keeping the entire coolant loop Continuous monitoring of eight coolant parameters and automatic dosing keep hall-scale liquid-cooling loops in specification between service visits Today DCX Liquid Cooling Systems announced worldwide’s first CDU system with built-in coolant control and treatment system. DCX integrated this coolant quality feature into it’s Facility Coolant Distribution Units: a family of 5-8 MW capable hyperscale-class coolant Distribution Units. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261014488003/en/ DCX announces the world’s first CDU with built-in coolant quality control and treatment - a new safety standard for hall-scale Liquid Cooling in critical AI infrastructure. The FDU monitors the chemistry of its coolant continuously and corrects it automatically with integrated electronic dosing pumps

STARTEEPO Sends Letter to Xerox Board in Advance of Third-Quarter Earnings19.10.2026 14:00:00 CEST | Press release

Company’s Third Largest Shareholder Expects Update on Increased Transparency, Strategic Review of Xerox Financial Services Business Unit, and Continued DeleveragingSTARTEEPO Chairman František Bostl to Address Xerox Investment at Skytop Conference in London STARTEEPO SICAV a.s. (“STARTEEPO”), which beneficially owns 7.34% of Xerox Holdings Corporation (“Xerox” or the “Company”) (NASDAQ: XRX) in stocks and options, today issued the following letter to the Xerox Board of Directors (the “Board”): October 19, 2026 The Board of Directors Xerox Holdings Corp. 401 Merritt 7 Norwalk, CT 06851 Dear Members of the Board: Our open letter to the Board in early September helped spark a lively conversation about the future of this iconic company among investors and throughout the print industry. Despite these efforts, Xerox’s share price still does not reflect the significant value we see in the Company, a gap recently confirmed by Citi’s downgrade of Xerox stock to reflect the challenge of executin

The Data Center Marketplace Is Booming, Inaugural Data Center World Europe Unites Data Center and Energy Decision-Makers and Expertsin Vienna19.10.2026 12:00:00 CEST | Press release

Data Center World Europe 2027 took place October 13-15 at VIECON – Vienna Congress & Convention Center in Austria Last week, Data Center World Europe, where data centre developers, AI and cloud providers, energy and utility operators, and solution providers come together to drive the development of an AI-ready, sustainable future, united leading operators, technologists, cloud providers, hyperscalers and energy management innovators over three days at VIECON – Vienna Congress & Convention Center in Vienna, Austria. It was co-located with the leading global network infrastructure event Network X, where data centre developers, AI and cloud providers, energy and utility operators, and solution providers come together to drive the development of an AI-ready, sustainable future, united leading operators, technologists, cloud providers, hyperscalers and energy management innovators. Tara Gibb, Senior Director, Data Center World Europe said, “The conference tackled the industry’s most urgent

BeOne Medicines Highlights Rapidly Accelerating Solid Tumor Franchise at ESMO 202619.10.2026 12:00:00 CEST | Press release

New data from four priority programs, including the GPC3x4-1BB bispecific antibody, CEA targeting ADC, CDK4 inhibitor, and brain-penetrant PRMT5 inhibitor underscore the depth of BeOne’s solid tumor pipelineMultiple TEVIMBRA abstracts reinforce breadth of evidence across lung and gastrointestinal cancers, including data in combination with ZIIHERA in HER2+ gastroesophageal cancer BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that data from across its rapidly progressing solid tumor portfolio will be presented at the European Society for Medical Oncology (ESMO) Congress 2026 on October 23-27 in Madrid. Presentations will highlight an accelerating pipeline of differentiated targeted therapies, alongside a broad body of evidence for TEVIMBRA® (tislelizumab), including a late-breaking rapid oral presentation on TEVIMBRA in combination with ZIIHERA® (zanidatamab) in HER2+ gastroesophageal adenocarcinoma (GEA). Priority pipeline data

First and Only Ulcerative Colitis Treat-to-Target Trial Shows Treating to Disease Clearance vs. Symptomatic Remission with ENTYVIO® (vedolizumab) Prolongs Time to First Disease-Related Complication19.10.2026 11:30:00 CEST | Press release

More than half of ENTYVIO patients who met their assigned treatment target reached disease clearance (composite of corticosteroid-free symptomatic, endoscopic and histologic remission) at Week 16VERDICT is the first trial to provide macroscopic and microscopic evidence of intestinal tissue repair associated with disease clearance in largely bio-naïve patients treated with an advanced therapy​ Takeda (TSE:4502/NYSE:TAK) announced new data from VERDICT (NCT04259138), showing that treating adults with intravenous ENTYVIO® (vedolizumab) to achieve corticosteroid-free (CSF) disease clearance versus CSF symptomatic remission alone, resulted in a significantly longer time to first ulcerative colitis (UC)-related complication (hazard ratio 0.33 [95% confidence interval 0.17-0.67]; P=0.0014), reducing UC complication risk by nearly 70 percent. VERDICT, a Phase 4 ENTYVIO clinical trial, provides the first prospective, randomized evidence that disease clearance is an achievable and clinically rel

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye